Heterocyclic Compounds

Matches 1 - 50 out of 30,948	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/099336A1	THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF The disclosure relates to thiadiazolyl derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.
WO/2024/101337A1	QUINAZOLINE DERIVATIVES Provided in one embodiment is a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing a splicing abnormality that causes onset or advance of a disease. The present disclosure provides in one embodiment a compoun...
WO/2024/102794A1	INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE Disclosed are compounds of Formula (I): pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosp...
WO/2024/099898A1	SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS The invention relates to substituted bi- and tricycles of the general formula (I),and the use of the compounds of the present invention as inhibitorsof HSET for the treatment and/or prevention of hyperproliferative diseases and disorders...
WO/2024/101336A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND One embodiment of the present invention provides a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing the splicing anomalies that are a factor in the onset or progression of disease. This disclosure relates t...
WO/2024/102810A1	BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific pro...
WO/2024/102922A1	INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE METHODS OF USE THEREOF The disclosure provides compounds, in part, compounds of Formula I or Formula II and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and meth...
WO/2024/099337A1	THIADIAZOLYL DERIVATIVES, COMPOSITIONS, AND USES THEREOF The disclosure relates to thiadiazolyl derivatives, for example, a compound of Formula (I), and pharmaceutical compositions thereof. The disclosure also relates to their uses in the treatment of a PolQ-mediated disease, e.g., cancer cont...
WO/2024/102849A1	BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also prov...
WO/2024/102901A1	USEFUL COMPOUNDS FOR MODULATING INFLAMMATION The present disclosure provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R3 and X are defined herein; pharmaceutical compositions; dosage forms comprising the compounds or pharmaceutical comp...
WO/2024/102924A1	INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE METHODS OF USE THEREOF The disclosure provides compounds, in part, compounds of Formula I or Formula II and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and meth...
WO/2024/099403A1	THIOETHER COMPOUND HAVING SOFT DRUG PROPERTY AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF A thioether compound having a soft drug property and a use thereof, and a pharmaceutical composition and a use thereof. The compound has a structural formula of formula I. A thioether structure in the compound has pharmacological activit...
WO/2024/102886A1	SUBSTITUTED BENZIMIDAZOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR9 Disclosed are compounds of Formulas (I): (I) or a salt thereof, wherein R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such comp...
WO/2024/099478A1	INHALABLE AROMATIC RING THIAZIDE AND ANALOG, PHARMACEUTICAL COMPOSITION CONTAINING INHALABLE AROMATIC RING THIAZINE, AND USE OF INHALABLE AROMATIC RING THIAZINE IN ANTI-INFLAMMATION AND ANTI-TUMOR A selective inhibitor of PI3Kδ, and a free base, isomer, solvate, pharmaceutically acceptable salt and other structural forms thereof. The compounds have significant antagonistic activity on PI3Kδ, and a pharmacokinetic study shows tha...
WO/2024/097948A1	DEGRADERS OF MDM2 AND USES THEREOF Provided herein are compounds, including compounds of Formula (I) (e.g., compounds of Formula (I-a)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-c...
WO/2024/095005A1	DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
WO/2024/097172A1	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
WO/2024/095012A1	PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS The invention relates to a compound of formula (Ia) and related aspects.
WO/2024/097897A1	LXR MODULATORS WITH BICYCLIC CORE MOIETY FOR TREATING DYSLIPIDEMIAS The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/...
WO/2024/094731A1	NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormalit...
WO/2024/097606A1	AHR AGONISTS The present disclosure relates to certain AHR agonist compounds, for example, having a general formula (I) to pharmaceutical compositions comprising the compounds, and to methods of using the compounds to treat immune-mediated diseases, ...
WO/2024/088237A1	LUMINESCENT MATERIAL, USE THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
WO/2024/088407A1	NITROGEN-CONTAINING FUSED RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are a nitrogen-containing fused ring compound as shown in formula (I), an intermediate thereof, a preparation method therefor and the use thereof. The compound has a DNA polymerase θ inhibitory activity, and can be used for tr...
WO/2024/089272A1	NEW INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE The present invention relates to the prevention and/or treatment of protein tyrosine kinase mediated diseases, in particular phosphatidylinositol 3-kinases (PI3Ks) mediated diseases. PI3Ks are well-known as oncology targets and several i...
WO/2024/088922A1	HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, W, Y, Z, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
WO/2024/091489A1	FUSED AZINES AS DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF Provided are compounds of the Formula (I):; or pharmaceutically acceptable salts thereof, which can be useful for the inhibition of Drp 1 and in the treatment of a variety of Drp 1l mediated conditions or diseases.
WO/2024/091024A1	COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
WO/2024/088282A1	PYRAZINAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF AS TYK2 INHIBITOR The present invention provides a pyridazine compound as shown in formula (II), a preparation method therefor, and uses thereof. Also disclosed are uses of the compound of the present invention or the pharmaceutical composition thereof in...
WO/2024/091538A1	COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
WO/2024/091551A1	CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF Crystalline forms and pharmaceutical compositions of a PRMTS inhibitor of formula (I), methods of making the pharmaceutical compositions of the PRMTS inhibitor of formula (I) and methods of using the PRMTS inhibitor of formula (I) or cry...
WO/2024/082724A1	PIM KINASE INHIBITOR IN COMBINATION WITH KRAS INHIBITOR It relates to the combination of PIM kinase inhibitor and a KRAS inhibitor for use in treating cancer, in a subject in need thereof. Also provided are compositions or kits comprising same. Furthermore, it also relates to a PIM kinase inh...
WO/2024/084447A2	AZETIDINYL BENZOXAZOLE COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS Compounds of formula (I) and an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3 and W, are as defined in the specification, are usef...
WO/2024/085695A1	NOVEL ALTIRATINIB DERIVATIVE, MANUFACTURING METHOD THEREFOR, AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF SKIN PIGMENTATION The present invention relates to a novel altiratinib derivative, a manufacturing method therefor, and a composition comprising same as an active ingredient for the prevention, alleviation, or treatment of skin pigmentation. The altiratin...
WO/2024/082917A1	CRYSTAL FORM A OF BUPIVACAINE-MELOXICAM SALT, SINGLE CRYSTAL THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are a crystal form A of bupivacaine-meloxicam salt, a single crystal thereof, a preparation method therefor and a use thereof. An X-ray powder diffraction pattern of the crystal form A of the bupivacaine-meloxicam salt has char...
WO/2024/086717A2	HETEROARYL ENHANCERS OF THE PARTICULATE GUANYLYL CYCLASE RECEPTOR A The present disclosure provides compounds of the formulae herein (e.g., Formula (I) and (V)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, a...
WO/2024/086252A1	NOVEL ATP-SENSITIVE POTASSIUM CHANNEL POTENTIATORS, THEIR PREPARATION AND USE The present disclosure relates to compounds of general formula (I) or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, methods for their preparation, the use of said compounds for use as a medicament, and their use in ...
WO/2024/085699A1	COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF The present disclosure provides a compound of a specific chemical structure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, which has excellent activity in te...
WO/2024/084360A1	PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 (PNPLA3) MODIFIERS The present invention relates to compounds of Formula A, and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such proce...
WO/2024/083137A1	FUSED HETEROCYCLIC AROMATIC HYDROCARBON COMPOUNDS, AND COMPOSITION AND USE THEREOF Provided in the present invention are novel fused heterocyclic aromatic hydrocarbon compounds or pharmaceutically acceptable salts thereof, a pharmaceutical composition containing same, and the use of same as a KIF18A inhibitor in preven...
WO/2024/084186A1	TREATMENT OF LEISHMANIASIS The presentation invention relates to compounds of formula (I) and pharmaceutical compositions thereof. The compounds may be used to treat an infection, such as a parasitic infection or a bacterial infection. In some embodiments, the com...
WO/2024/083237A1	SUBSTITUTED HETEROARYL BICYCLIC COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF The disclosure provides substituted heteroaryl bicyclic compounds as represented in Formula I and the use thereof, wherein, A1, A2, B1, B2, B3, ring Z, L, Cy1 and Cy2 are defined herein. The compounds of Formula I can be used to prevent ...
WO/2024/086705A2	BICYCLIC ENHANCERS OF THE PARTICULATE GUANYLYL CYCLASE RECEPTOR A The present disclosure provides compounds of formulae herein (e.g., Formula (I- a) and (I-b)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, ...
WO/2024/083886A1	RNA-BINDING MOLECULES WITH A SMALL CORE SCAFFOLD (R-SCORE) AND USES THEREOF The present invention relates to novel RNA-binding azetidine compounds of general formula (I) and stereoisomeric forms, hydrates, solvates and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing s...
WO/2024/078436A1	HETEROCYCLIC PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF The present disclosure discloses a compound having formula (I) or a pharmaceutically acceptable salt thereof which acts as a USP1 inhibitor, a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt the...
WO/2024/080361A1	IMIDAZOLE DERIVATIVE The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The compound of the invention has excellent α1A adrenergic receptor agonist activity and is useful as a proph...
WO/2024/080655A1	COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE HAVING SAME The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...
WO/2024/081345A1	BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS Novel PI3K inhibitors of the general formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway, formula (1), wherein R1 to...
WO/2024/081927A1	COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
WO/2024/078620A1	NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical comp...
WO/2024/080788A1	NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF The present invention relates to a novel tricycle derivative compound and uses thereof, more specifically to a novel tricycle derivative compound having inhibitory activity for methionine adenosyltransferase 2A (MAT2A) and uses thereof.

Matches 1 - 50 out of 30,948	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >